Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZELAPAR

« Back to Dashboard
Zelapar is a drug marketed by Valeant Pharm Intl and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

This drug has sixty-five patent family members in thirty-three countries.

The generic ingredient in ZELAPAR is selegiline hydrochloride. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.

Summary for Tradename: ZELAPAR

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Clinical Trials for: ZELAPAR

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

Evaluation of Adhesion and Dermal Tolerability of EMSAM
Status: Completed Condition: Healthy

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
Status: Completed Condition: Healthy

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Status: Completed Condition: Major Depressive Disorder

A Pilot Study Assessing EmSam in Bipolar Depression
Status: Terminated Condition: Bipolar Depression

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Status: Completed Condition: Parkinson's Disease

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
Status: Completed Condition: Cognitive Disorders; HIV Infections

A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
Status: Completed Condition: Alzheimer Disease, Healthy Volunteer

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
Status: Completed Condition: Marijuana Abuse

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
Status: Recruiting Condition: Parkinson's Disease; Erectile Dysfunction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006RXYes5,648,093<disabled>Y <disabled>
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006RXYes6,423,342<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZELAPAR

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 20065,648,093<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZELAPAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,558,880 Pharmaceutical and other dosage forms<disabled in preview>
5,120,549 United States Patent: 5120549   ( 1<disabled in preview>
5,215,756 Preparation of pharmaceutical and other matrix systems by solid-state dissolution<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZELAPAR

Country Document Number Publication Date
Denmark0460185Sep 27, 1999
Denmark0814770Nov 05, 2001
China1085081Apr 13, 1994
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc